App-Quantinova.ai

Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG e. coli L-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children-s Oncology Group (COG) study AALL07P4.

Anne L. Angiolillo - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Methotrexate

Trends in body mass index (BMI) during and after treatment for standard risk (SR) acute lymphoblastic leukemia (ALL): A report from the Childrens Oncology Group (COG).

Susan Joy Lindemulder - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

Fever at diagnosis of pediatric acute lymphoblastic leukemia (ALL): Are antibiotics really necessary-

Monica Khurana - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Minimal residual disease by flow cytometry at the end of chemotherapy for remission induction in pediatric patients with acute lymphoblastic leukemia: Experience from a center in a low-income country.

Eloy Perez - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

YM155 sensitivity in pediatric acute lymphoblastic leukemia.

Bill H. Chang - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

YM155

Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HR-ALL): A report from the Childrens Oncology Group study AALL0232.

Eric Larsen - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

Dexamethasone

Country specific serum IgE reactivity profile and concordance with allergic history among acute lymphoblastic leukemia children and controls.

Maria Stella Lariou - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Association of bone mineral density with incidental renal stone in long-term survivors of childhood acute lymphoblastic leukemia.

Prasad Laxman Gawade - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

N/A

Preliminary results of acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic cell transplantation: A single center experience

A. I. E. Tekguenduez - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

The clinical and therapeutic drug monitoring of oral and intravenous busulfan in patients with acute leukemia that underwent to stem cell transplantation with a test dose of busulfan

I. Esteves - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Busulfan

Comparison of the conditioning regimens with or without TBI in acute lymphoblastic leukemia patients: Experience of a single center

M. Yeral - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Meaning of mixed chimerism by short tandem repeat PCR in allogeneic stem cell transplantation

B. Kim - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

N/A

Relapse of Pediatric Leukemia Following Hematopoietic Stem Cell Transplantation: a Single Center Experience

B. Akinci - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

CD34-enriched, T-cell repleted PBSCTs from unrelated mismatch donors as alternative stem cell source in high-risk pediatric acute lymphoblastic leukemia: A single center experience.

J.-S. Kuehl - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

Cyclosporine A

Allografting after reduced intensity conditioning with thymoglobulin followed by early withdrawal of prophylactic immunosuppression could be an effective approach to the patients with acute lymphoblastic leukemia

L. Raida - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Mycophenolate mofetil

Allogeneic stem cell transplantation in children with relapsed and refractory leukemia

Z. Kaya - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

COMPAR SON AND EVALUATION OF QUAL TY OF L FE OF ACUTE MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WHO HAD RECEIVED HAPLOIDENTICAL OR ALLOGENEIC STEM CELL TRANSPLANTATION WITH FUNCT ONAL ASSESSMENT OF CANCER THERAPY (FACT-G) SCALE

B. Sarita? - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Improving results of allogeneic HCT for adults with acute lymphoblastic leukemia: an analysis from Acute Leukemia Working Party of the EBMT

S. Giebel - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Long-term outcomes of reduced-intensity conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in first complete remission

S. Lee - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Cyclosporine eent

Low pre-transplant 25-hydroxyvitamin D3 predicts relapse and survival in male but not in female patients undergoing allogeneic stem cell transplantation

A. Radujkovic - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

cholecalciferol

Filters

2187 Abstracts